Organization
Michael M. Pham
1 clinical trial
Clinical trial
A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung DiseaseStatus: Terminated, Estimated PCD: 2024-02-23